Mantle Cell Lymphoma | Clinical

Global ZILO-301 Study of Zilovertamab for MCL to Initiate in Q3 2022

April 28, 2022

Oncternal Therapeutics announced it would terminate its study of ONCT-216 for patients with Ewing sarcoma and prioritize its phase 3 ZILO-301 study of zilovertamab plus ibrutinib for patients with relapsed/refractory mantle cell lymphoma.